科金特生物科技

最新新闻

• 评级变动
  J.P. Morgan Sticks to Its Buy Rating for Cogent Biosciences (COGT)
  TipRanks · 2026/3/14
• 评级变动
  Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $52
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  Needham Maintains Cogent Biosciences(COGT.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  Guggenheim Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $52
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  UBS Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/6/1
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL), Cogent Biosciences (COGT) and Anteris Technologies Global Corp. (AVR)
  TipRanks · 2026/6/1
• Wedbush Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Announces Target Price $62
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $64
  \u5e02\u573a\u8d44\u8baf · 2026/3/14
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (AARD), Upstream Bio, Inc. (UPB) and Cogent Biosciences (COGT)
  TipRanks · 2026/3/2
• 评级变动
  A Quick Look at Today's Ratings for Cogent Biosciences(COGT.US), With a Forecast Between $45 to $55
  \u5e02\u573a\u8d44\u8baf · 2026/5/6
• 评级变动
  J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/1
• 评级变动
  Guggenheim Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/4/2
• H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• 评级变动
  H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $52
  \u5e02\u573a\u8d44\u8baf · 2026/4/2
• Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $55
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  Jefferies Initiates Cogent Biosciences(COGT.US) With Buy Rating, Announces Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/3/16
• 评级变动
  Jefferies Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $48
  \u5e02\u573a\u8d44\u8baf · 2026/2/19
• 评级变动
  Stifel Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/6/15

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。